TAMPA, FL -- (MARKET WIRE) -- 12/14/05 -- Stem Cell Therapy International, Inc. (OTC: SCII), a leading company in the field of research and development of stem cell transplantation therapy and regenerative medicine, today appointed Igor Katkov, Ph.D., to its Medical and Scientific Advisory Board. Dr. Katkov holds an academic position at the University of California San Diego (UCSD) and he is a member of The Burnham Institute Stem Cell Center in La Jolla, CA. His expertise combines a knowledge of physics, biology, biochemistry and stem cell biology. Since 1988, he has been a scientific consultant to the Institute for Cryobiology and Cryomedicine in Kharkov, Ukraine. He has gained unique experience in working with adult, cord blood, and embryonic stem cells, and is an active consultant in organizing a cord blood stem cell bank in St. Petersburg, in the Russian Federation.

As a member of the SCTI Medical and Scientific Advisory Board, Dr. Katkov will review new technologies and business opportunities, he will develop and write scientific papers and abstracts on SCTI stem cell (SC) technology and patient studies for publication in scientific and industry-related journals as well as obtaining research and development funding grants for stem cell-related projects. One of his major focuses will be QC of the SC samples, monitoring of SC processing, shipping, and maintenance of the cell quality after resuscitation, as well as increasing efficacy of processing, cryopreservation and storage protocols.

Calvin C. Cao, Chairman and Chief Executive Officer of Stem Cell Therapy International, said, "We are proud to announce that Igor Katkov has agreed to join the SCTI Medical and Scientific Advisory Board. He is a world-class scientist in the field of stem cell research, cell processing, preservation and stabilization and will be a substantial contributor to SCTI's future scientific and business development."

In addition to his current associations with UCSD, which dates back to January 2002, and with the Burnham Institute, Dr. Katkov has worked with private cell research companies in the United States and Canada, at the Oak Ridge National Laboratory and the University of Tennessee. Before 1995, he headed up and worked for numerous private and public research organizations in Kharkov, Ukraine. He holds a degree in Cell Biophysics and Biomedical Engineering from Kharkov State University, 1979, and received his Ph.D. in Cell Biology and Physiology with emphasis on Cryobiology in 1985 from the Research Institute for Animal Husbandry, Kharkov, Ukraine.

With the enactment of Proposition 71 in California in November 2004, a fund of $3 billion dollars was created to promote stem cell research. Since that time, four other states, New Jersey, Connecticut, Illinois and Wisconsin, have allocated significant funds for stem cell research. For additional information on SCTI's research and treatment programs please visit our website @ www.scticorp.com.

About Stem Cell Therapy International (SCTI)

Stem Cell Therapy International, Inc. is engaged in the field of research and development of regenerative medicine. SCTI manufactures biological solutions that are currently being used in the treatment of patients suffering from degenerative disorders of the human body such as Alzheimer's, Parkinson's Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer. The Company has established agreements with highly specialized, professional medical treatment facilities around the world in locations where stem cell transplantation therapy is approved by the appropriate local government agencies. SCTI intends to provide these biological solutions containing stem cell products in the United States as well, to universities, institutes and privately funded laboratory facilities for research purposes and clinical trials. Their products, which are available now, include various biological solutions containing fetal stem cells, adult stem cells and stem cell which are extracted from umbilical cord blood.

Forward-Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct.

Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.

For more information, please contact:

Stem Cell Therapy International
Calvin C. Cao
Chairman and CEO
Stem Cell Therapy International
E: calvin@scticorp.com

Investor Relations
Arun Chakraborty
Investor Relations
Stern & Co.
T: 212-888-0044
E: achakrab@sternco.com

Media Relations
Stan Froelich
VP, Media Relations
Stern & Co.
T: 212-888-0044
E: sfroelich@sternco.com